Prediabetes Market Size & Growth Forecast 2027–2036, By Segments (Drug Class, Age Group), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Prediabetes Market size was worth USD 385 million in 2026 and is poised to grow at a 9.12% CAGR between 2027 and 2036, crossing USD 921.52 million by 2036. The industry revenue for 2027 is assessed at USD 414.57 million.
Get more details on this report
Request Free Sample ReportPrediabetes Market Intelligence Snapshot
Regional Market Dynamics
- North America holds 43.78% share due to strong screening programs, established preventive care pathways, and high patient engagement in early metabolic risk management.
- Growth is driven by rising urbanization, lifestyle changes, improving diagnostic access, and expanding preventive healthcare programs, supporting an 8.25% CAGR.
Segment Momentum
- Diguanide held a 75.65% market share in 2026 because it remains the established choice for early pharmacological intervention, supporting consistent prescribing patterns beyond lifestyle management.
- The Elderly (50+) segment is the fastest-growing because ongoing medical supervision increases diagnosis rates and encourages continuous treatment and monitoring after prediabetes is detected.
Market Expansion Drivers
- Rising global prevalence of obesity and sedentary lifestyles increasing prediabetes diagnosis rates.
- Increasing adoption of continuous glucose monitoring technologies supporting early-stage diabetes management.
- Expanding preventive healthcare initiatives encouraging early screening and intervention for metabolic disorders.
Leading Market Participants
- Top companies in the prediabetes market include Novo Nordisk A/S (Denmark), AstraZeneca PLC (United Kingdom), Pfizer Inc. (United States), Bristol-Myers Squibb Company (United States), Valbiotis SA (France), Boston Pharmaceuticals, Inc. (United States), Resverlogix Corp. (Canada), Caelus Health B.V. (Netherlands), Aphaia Pharma AG (Switzerland), Eli Lilly and Company (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 385 million
- 2027 Estimated Market Size: USD 414.57 million.
- Projected Market Size: USD 921.52 million by 2036
- Growth Forecast: 9.12% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Diguanide (Drug Class) | Adults (18-49) (Age Group)
- Emerging Opportunity Segment: Glucagon-like Peptide-1 Agonists (GLP-1) (Drug Class) | Elderly (50+) (Age Group)
Market Growth Drivers and Industry Trends
Rising global prevalence of obesity and sedentary lifestyles increasing prediabetes diagnosis rates
The prediabetes market is being influenced by the growing prevalence of obesity and increasingly sedentary lifestyles, both of which are closely associated with impaired glucose regulation and elevated metabolic risk. Reduced physical activity, unhealthy dietary patterns, and weight-related metabolic changes can increase the likelihood of developing prediabetes, prompting greater attention to screening among at-risk populations. As healthcare providers place greater emphasis on identifying metabolic abnormalities before progression to type 2 diabetes, more individuals are entering diagnosis and monitoring pathways.
Increasing adoption of continuous glucose monitoring technologies supporting early-stage diabetes management
Continuous glucose monitoring is providing patients and healthcare professionals with more detailed insight into glucose fluctuations, supporting individualized approaches to managing metabolic health. For the prediabetes market, wider access to these technologies can encourage closer monitoring of glucose patterns and help individuals understand how diet, physical activity, medication, and other lifestyle factors influence glycemic control. The availability of real-time and longitudinal glucose information also supports more informed behavioral interventions among people at elevated risk of diabetes.
Expanding preventive healthcare initiatives encouraging early screening and intervention for metabolic disorders
The prediabetes market is gaining support from healthcare strategies that prioritize prevention, risk identification, and early intervention rather than waiting for metabolic disorders to progress. Screening programs can identify individuals with elevated glucose levels who may benefit from dietary changes, increased physical activity, weight management, and structured medical monitoring. Greater public awareness of diabetes risk is also encouraging people with relevant risk factors to participate in routine health assessments, strengthening the role of early metabolic screening in clinical care.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global prevalence of obesity and sedentary lifestyles increasing prediabetes diagnosis rates | 1.80% | Moderate | North America, Asia Pacific | High | Near Term |
| Increasing adoption of continuous glucose monitoring technologies supporting early-stage diabetes management | 1.50% | Moderate | North America, Europe | Medium | Mid Term |
| Expanding preventive healthcare initiatives encouraging early screening and intervention for metabolic disorders | 1.20% | High | Europe, Asia Pacific | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
Holding the largest share of the prediabetes market at 43.78% in 2026, North America benefits from strong awareness of metabolic health, widespread screening initiatives, and increasing emphasis on early identification of individuals at risk of developing diabetes. Healthcare systems across the region are placing greater importance on preventive care, lifestyle intervention, and monitoring of blood glucose levels to reduce the progression of metabolic disorders. Growing demand for diagnostic testing, digital health tools, nutritional interventions, and structured disease-management programs is supporting market development. Established healthcare infrastructure and greater access to preventive health services further strengthen the region's market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region, driven by changing dietary patterns, increasing urbanization, sedentary lifestyles, and growing awareness of diabetes prevention. Healthcare providers and public health authorities are placing greater focus on identifying elevated blood glucose at an earlier stage and encouraging lifestyle changes before progression to diabetes. Expanding healthcare access and improving diagnostic capabilities are also enabling broader screening and monitoring. At the same time, rising consumer interest in healthier lifestyles and the adoption of digital health solutions are creating additional opportunities for prediabetes management, supporting continued expansion of the market across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Monitoring IntegrationGermany is strengthening the prediabetes market through integrated screening in primary care and structured disease monitoring. German healthcare systems are emphasizing continuous metabolic tracking and nutritional intervention to reduce progression into diabetes.
France 🇫🇷
Nutrition-Led PreventionFrance is emphasizing structured nutritional counseling and preventive diagnostics in the prediabetes market. French healthcare initiatives are increasingly linking dietary intervention with regular metabolic assessments to support earlier treatment pathways.
Italy 🇮🇹
Community Care ExpansionItaly’s prediabetes market is shaped by community healthcare engagement and early-stage metabolic monitoring. Italian healthcare providers are broadening access to preventive screening and patient education programs to address long-term disease burden.
Japan 🇯🇵
Precision Lifestyle ManagementJapan’s prediabetes market is focused on individualized dietary planning and regular health assessments. Japanese healthcare providers are incorporating wearable technologies and behavior-driven programs to support long-term glucose stability and risk management.
South Korea 🇰🇷
Digital Wellness ProgramsSouth Korea is aligning the prediabetes market with app-based health coaching and real-time glucose tracking. Providers in South Korea are integrating wellness technologies with preventive healthcare models to improve patient adherence and lifestyle management.
United States 🇺🇸
Preventive Screening PushThe U.S. prediabetes market is driven by rising adoption of digital glucose monitoring and preventive care programs. Healthcare providers in the U.S. are prioritizing early diagnosis, lifestyle intervention platforms, and personalized metabolic health management.
Segment Leadership and Growth Trends
Prediabetes Market Share (%), by Drug Class, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportDrug Class Segment Analysis: Diguanide (Largest Segment) vs Glucagon-like Peptide-1 Agonists (GLP-1) (Fastest-Growing Segment)
The diguanide segment led the prediabetes market in 2026, accounting for a 75.65% share, supported by its established role in managing glucose metabolism and addressing insulin-related metabolic abnormalities. Familiarity among healthcare professionals, established clinical use, and its positioning within conventional approaches to glucose management contribute to continued utilization. Growing awareness of prediabetes and the importance of delaying or managing progression toward more advanced metabolic disease further supports demand for established drug classes.
Glucagon-like peptide-1 agonists (GLP-1) are gaining momentum as interest grows in therapies capable of addressing broader metabolic concerns alongside glucose regulation. Their relevance to weight management and metabolic health is increasing attention toward GLP-1-based approaches among patients and healthcare providers. Continued therapeutic innovation and growing recognition of the interconnected nature of obesity, insulin resistance, and prediabetes are supporting the segment's rapid expansion.
Age Group Segment Analysis: Adults (18-49) (Largest Segment) vs Elderly (50+) (Fastest-Growing Segment)
Adults aged 18-49 represented the largest age-group segment of the prediabetes market in 2026, reflecting the importance of early identification and management of metabolic risk among working-age populations. Increasing exposure to sedentary lifestyles, dietary changes, and other lifestyle-related risk factors is strengthening demand for screening and interventions within this demographic. Greater awareness of the long-term consequences of impaired glucose regulation is also encouraging earlier engagement with preventive healthcare.
The elderly segment is expanding rapidly as metabolic disorders become an increasingly important concern among older populations. Age-related changes in glucose metabolism, the accumulation of chronic health risks, and the need for closer monitoring are increasing demand for appropriate prediabetes management. Healthcare systems are also placing greater emphasis on early intervention and comprehensive metabolic care, supporting stronger attention to this age group.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Drug Class | Diguanide, Thiazolidinediones, Glucagon-like Peptide-1 Agonists (GLP-1), SGLT2 Inhibitors, DPP-4 Inhibitors, Others | Diguanide | Glucagon-like Peptide-1 Agonists (GLP-1) |
| Age Group | Children (12-18 Years), Adults (18-49), Elderly (50+) | Adults (18-49) | Elderly (50+) |
Competitive Landscape and Market Positioning
Leading companies in the prediabetes market:
1. Novo Nordisk A/S (Denmark)
2. AstraZeneca PLC (United Kingdom)
3. Pfizer Inc. (United States)
4. Bristol-Myers Squibb Company (United States)
5. Valbiotis SA (France)
6. Boston Pharmaceuticals Inc. (United States)
7. Resverlogix Corp. (Canada)
8. Caelus Health B.V. (Netherlands)
9. Aphaia Pharma AG (Switzerland)
10. Eli Lilly and Company (United States)
The prediabetes market is expanding due to rising awareness of early metabolic risk management and preventive healthcare approaches. Innovation in diagnostic and lifestyle intervention solutions is improving early detection and management outcomes. The market is increasingly focused on proactive metabolic health intervention strategies.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Novo Nordisk A/S (Denmark) | |||||||
| AstraZeneca PLC (United Kingdom) | |||||||
| Pfizer Inc. (United States) | |||||||
| Bristol-Myers Squibb Company (United States) | |||||||
| Valbiotis SA (France) | |||||||
| Boston Pharmaceuticals Inc. (United States) | |||||||
| Resverlogix Corp. (Canada) | |||||||
| Caelus Health B.V. (Netherlands) | |||||||
| Aphaia Pharma AG (Switzerland) | |||||||
| Eli Lilly and Company (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Planttech | May-26 | Planttech published clinical trial results in Nutrients demonstrating that its inositol-rich carob liquid concentrate, LVLD, significantly reduced HbA1c, fasting glucose, and insulin resistance in 52 prediabetic adults. These findings validate the potential of functional nutraceutical interventions in managing metabolic dysfunction and offer a non-pharmaceutical approach for improving insulin sensitivity in prediabetic populations. |
| ŌURA | May-26 | ŌURA partnered with the Department of Health – Abu Dhabi to launch a joint research program investigating the use of continuous wearable biometric data for preventive healthcare. The study focuses on leveraging real-time physiological monitoring to enhance early risk detection and develop proactive, data-driven intervention strategies for chronic metabolic conditions like prediabetes. |
| Sigrid Therapeutics | Mar-25 | Sigrid Therapeutics achieved a key commercial milestone by securing U.S. market access for its SiPore® technology following successful SHINE study outcomes. The platform, which targets blood sugar and weight management, is now positioned for expanded adoption as a clinically validated metabolic intervention tool within preventive diabetes care and broader metabolic health management programs. |
| Teladoc Health | Feb-25 | Teladoc Health acquired Catapult Health for $65 million, significantly strengthening its virtual care ecosystem for chronic condition management. The acquisition enhances the company’s ability to provide at-home preventive testing and integrated digital health services, facilitating earlier identification and more effective long-term management of metabolic risks such as prediabetes. |
| Eli Lilly | Dec-24 | Eli Lilly’s Zepbound (tirzepatide) received FDA approval for the treatment of obstructive sleep apnea in adults with obesity. This regulatory milestone expands the therapeutic footprint of the company’s metabolic portfolio, reinforcing its strategic focus on cardiometabolic innovation and drug-based management of obesity-related comorbidities that are highly correlated with prediabetes progression. |
| Dexcom | Aug-24 | Dexcom launched its Stelo continuous glucose monitoring (CGM) system for over-the-counter use, specifically targeting adults with type 2 diabetes or prediabetes who do not require insulin. This 15-day wearable device expands access to real-time metabolic monitoring, empowering consumers with actionable data to support lifestyle interventions and early preventive health management. |
| Aphaia Pharma | Jun-24 | Aphaia Pharma reported positive Phase 2 clinical trial results for its oral glucose formulation, APHD-012, which met its primary endpoint of improved glucose tolerance in prediabetic patients. The study confirmed that the treatment, which restores endogenous nutrient-sensing pathways in the gastrointestinal tract, significantly reduced blood glucose levels with a favorable safety profile compared to placebo. |
| Droobi Health | Jan-24 | Droobi Health merged with India-based Smit.fit to form DroobiSmit, a comprehensive healthtech platform dedicated to digital chronic disease management. The merger leverages synergies in lifestyle intervention and clinical monitoring to strengthen the delivery of personalized care pathways, improving regional access to digital tools for diabetes and prediabetes prevention and management. |
| Omada Health | Jan-24 | Omada Health entered a strategic partnership with Amazon to integrate its chronic condition management programs into Amazon’s healthcare ecosystem. The collaboration aims to scale the delivery of virtual, lifestyle-focused preventive care, making it easier for individuals at risk of or living with prediabetes to access evidence-based programs and ongoing health support. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Prediabetes Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Diagnosis Method | Fasting Plasma Glucose, Oral Glucose Tolerance Test, Hemoglobin A1c, Other Diagnostic Tests |
| Care Setting | Hospitals and Clinics, Diagnostic Laboratories, Physician Offices, Other Care Settings |
| Treatment Approach | Lifestyle Intervention, Pharmacological Intervention, Combination Approach |
Prediabetes Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Population Screening and Early Detection Opportunity Assessment |
|
| Patient Journey and Care Gap Analysis |
|
| Risk Stratification and Intervention Prioritization |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of prediabetes?
What is the projected value of the prediabetes industry by 2036?
How are continuous glucose monitoring technologies supporting growth in the prediabetes market?
Why are preventive healthcare initiatives becoming increasingly important in the prediabetes market?
Why does Diguanide dominate the prediabetes market?
Which age group is experiencing the fastest growth in the prediabetes market?
Why does North America hold largest share in prediabetes market?
What is driving Asia Pacific growth in prediabetes market?
Which companies dominate the prediabetes landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization